https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):2220629
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-06-30 / Hum Vaccin Immunother 2023 Aug;19(2):22206292023-06-30 00:00:002023-06-30 00:00:00A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-05-03 / Hum Vaccin Immunother 2023 May;:21984672023-05-03 00:00:002023-05-03 00:00:00Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-624
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-6242023-04-21 00:00:002023-04-21 00:00:00Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-12 / Biomed Pharmacother 2023 Jun;162:114685
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-12 / Biomed Pharmacother 2023 Jun;162:1146852023-04-12 00:00:002023-04-12 00:00:00Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-03 / Pharmaceutics 2023 Apr;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-03 / Pharmaceutics 2023 Apr;15(4)2023-04-03 00:00:002023-04-03 00:00:00The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-01 / J Cancer Res Ther 2023 Apr;19(Supplement):S52-S58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-01 / J Cancer Res Ther 2023 Apr;19(Supplement):S52-S582023-04-01 00:00:002023-04-01 00:00:00Personalized dendritic cell vaccination in cancer therapy: An evidence-based research study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-07 / Cancer Immunol Immunother 2023 Mar;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-07 / Cancer Immunol Immunother 2023 Mar;2023-03-07 00:00:002023-03-07 00:00:00A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):292023-03-02 00:00:002023-05-30 16:16:10Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-16 / Biochem Biophys Res Commun 2023 Apr;653:106-114
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-16 / Biochem Biophys Res Commun 2023 Apr;653:106-1142023-02-16 00:00:002023-02-16 00:00:00Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
